Research Summary

I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer.

I am the Program Leader for GU Medical Oncology program and Associate Director for Clinical Research in the UCSF Helen Diller Family Comprehensive Cancer Center.

My research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.

Research Funding

  • March 1, 2021 - February 28, 2026 - Precision targeting of T cell cytotoxicity with PET , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA258297
  • December 1, 2020 - November 30, 2025 - Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA256740
  • June 1, 2017 - May 31, 2022 - Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA215694
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA229354

Education

Northwestern University, Evanston, IL, BA, 1999-2002, Psychology
Northwestern University Feinberg School of Medicine, Chicago, IL, MD, 2002-2006, Medicine

Honors & Awards

  • 2001
    James Alton James Scholarship, Northwestern University
  • 2002
    James A. Patten Scholarship, Northwestern University
  • 2002
    Phi Beta Kappa Centennial Award, Northwestern University
  • 2002
    Summa Cum Laude, Northwestern University
  • 2004
    Department of Medicine Chairman’s Award, Northwestern University School of Medicine
  • 2005
    Member Alpha Omega Alpha medical honor society
  • 2011
    Pfizer Fellowships in Oncology Award in collaboration with UCSF Division of Hematology/Oncology, Department of Medicine
  • 2012
    Young Investigator Award, American Society of Clinical Oncology/Conquer Cancer Foundation
  • 2012
    Inaugural Recipient, Ronald A. Rosenberg Fellowship in Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2013
    Alliance Cooperative Group Scholar Award
  • 2014
    The Sence Foundation Award
  • 2015
    Prostate Cancer Foundation Young Investigator Award
  • 2016
    Department of Defense Prostate Cancer Research Program Physician Research Training Award
  • 2016
    UCSF Helen Diller Family Early Phase Clinical Research Support Grant
  • 2016
    National Cancer Institute Cancer Clinical Investigator Team Leadership Award

Selected Publications

  1. Armstrong AJ, Morris MJ, Abida W, Aggarwal RR, Antonarakis ES, Attard G, Beltran H, Bryce A, Carducci MA, Cheng HH, Chen DL, Chi KN, Childs DS, Dahut W, Emmett L, Fizazi K, Gafita A, George DJ, Hermann K, Hofman MS, Hope T, Hussain M, Kelly WK, Kessler E, Kuo PH, Lang J, Liu G, Marshall CH, Morgans AK, McKay RR, Nanus D, Nelson P, Paller C, Reichert ZR, Ryan CJ, Sartor AO, Schöder H, Schwartz LH, Sharifi N, Stadler WM, Stein M, Sternberg CN, Szmulewitz RZ, Tagawa ST, Sokolova AO, Wyatt AW, Yamoah K, Yu EY, Halabi S, Scher HI, PCWG4 Writing Group. Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4. J Clin Oncol. 2026 Feb 26; JCO2502834. View on PubMed
  2. Zhu X, Alvarez EA, Umetsu SE, Chapman JS, Chen LM, Ueda S, Henderson S, Nguyen P, Calabrese S, Russell J, Aguilar J, Smith SA, Shah N, Feeney L, Van Ziffle J, Turski ML, Ko AH, Munster PN, Ashworth A, Collisson EA, Aggarwal RR. Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies. Clin Cancer Res. 2026 Feb 13. View on PubMed
  3. Bidkar AP, Bidlingmaier S, Wadhwa A, Mayne E, Raveendran A, Naik S, Xue C, Basak M, Bobba KN, Patiño-Escobar B, Greenland N, Camara Serrano JA, Steri V, Chou J, Wiita A, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates. Clin Cancer Res. 2026 Jan 22. View on PubMed
  4. De Souza AL, Hadfield MJ, Lu S, Golijanin DJ, Wood R, Margolis J, Anderson K, Olszewski AJ, Holder SL, El-Deiry WS, Aggarwal RR, Mega AE, Carneiro BA. BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Cancer Res Commun. 2025 Dec 01; 5(12):2142-2148. View on PubMed
  5. Lin C, Hadfield MJ, Santopietro A, Lagos G, Cheng L, El-Deiry WS, Aggarwal R, Mega A, Hyams E, Carneiro BA. The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. NPJ Precis Oncol. 2025 Nov 14; 9(1):351. View on PubMed
  6. Oseran AS, Aggarwal R, Wadhera RK. Cardiovascular Risk Factor Management in Medicare Advantage and Traditional Medicare. Circ Cardiovasc Qual Outcomes. 2025 Nov; 18(11):e012143. View on PubMed
  7. Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clin Cancer Res. 2025 Sep 15; 31(18):3854-3863. View on PubMed
  8. Sirohi D, Cornelia Ding CK, Stohr BA, Balassanian R, Vohra P, Aggarwal R, Chan E, Greenland NY. The utility of next-generation sequencing in metastatic prostate cancer FNA biopsies. Cancer Cytopathol. 2025 Sep; 133(9):e70038. View on PubMed
  9. Iagaru A, Suarez JF, Behr S, Aggarwal R, Paredes P, Buffi N, Penhoat T, Ceci F, Walz J, Doumerc N, Coulanges M, Xu Z, Seigne C, Wilke C, Catafau AM, Fanti S, Maurer T, GuideView study investigators. Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. J Nucl Med. 2025 Aug 01; 66(8):1232-1238. View on PubMed
  10. Fanti S, Robles Barba JJ, Behr S, Maurer T, Paredes P, Walz J, Duch J, Perdigo MS, Mainta IC, Bonnefoy PB, Coulanges M, Tang J, Seigne C, Wilke C, Catafau AM, Iagaru A, Aggarwal R. Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study. J Nucl Med. 2025 Aug 01; 66(8):1210-1216. View on PubMed
  11. Chen HY, de Kouchkovsky I, Bok RA, Ohliger MA, Wang ZJ, Gebrezgiabhier D, Nickles T, Carvajal L, Gordon JW, Larson PEZ, Kurhanewicz J, Aggarwal R, Vigneron DB. Correction: Chen et al. Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized 13C MRI-A Correlative Study with Clinical Outcomes. Cancers 2025, 17, 2211. Cancers (Basel). 2025 Jul 30; 17(15). View on PubMed
  12. Bidkar AP, Peter R, Wadhwa A, Bobba KN, Bidlingmaier S, Meher N, Chou J, Greenland N, Dasari C, Naik S, Raveendran A, Basak M, Camara Serrano JA, Steri V, Kogan S, Oskowitz A, He J, Wilson DM, Aggarwal R, Sriram R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. Clin Cancer Res. 2025 Jul 15; 31(14):2963-2977. View on PubMed
  13. Kumaraswamy A, Hu YM, Yates JA, Zhang C, Rodansky E, Khokhani D, Flores D, Duan Z, Zhang Y, Tabatabaei S, Slottke R, Ye S, Lara P, Foye A, Ryan CJ, Quigley DA, Huang J, Aggarwal R, Reiter RE, Wicha MS, Beer TM, Rettig M, Gleave M, Evans CP, Witte ON, Stuart JM, Thomas GV, Feng FY, Small EJ, Xia Z, Alumkal JJ. Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer. NPJ Precis Oncol. 2025 Jul 07; 9(1):223. View on PubMed
  14. Chen HY, de Kouchkovsky I, Bok RA, Ohliger MA, Wang ZJ, Gebrezgiabhier D, Nickles T, Carvajal L, Gordon JW, Larson PEZ, Kurhanewicz J, Aggarwal R, Vigneron DB. Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized 13C MRI-A Correlative Study with Clinical Outcomes. Cancers (Basel). 2025 Jul 01; 17(13). View on PubMed
  15. Kwon DH, Scheuner MT, McPhaul M, Hearst EL, Sumra S, Ursem C, Walker E, Wang S, Kaur G, Nesheiwat S, Huang FW, Aggarwal RR, Belkora J. Veterans' Decision Making for Prostate Cancer Germline Testing After Informed Consent With Their Oncologist: A Mixed-Methods Study. JCO Oncol Pract. 2025 Jun 24; OP2500078. View on PubMed
  16. Duan Z, Shi M, Kumaraswamy A, Lin D, Khokhani D, Wang Y, Zhang C, Flores D, Rodansky E, Swaim OA, Storck WK, Beck HN, Patel RA, Sayar E, Hanratty BP, Xue H, Dong X, Maylin ZR, Wan R, Quigley DA, Sjöström M, Hu YM, Zhao F, Xia Z, Cheng S, Yu X, Feng FY, Zhang L, Aggarwal R, Small EJ, Ravikumar V, Rao A, Bedi K, Lee JK, Morrissey C, Coleman I, Nelson PS, Corey E, Udager AM, Rebernick RJ, Cieslik MP, Chinnaiyan AM, Yates JA, Haffner MC, Wang Y, Alumkal JJ. PROX1 is an early driver of lineage plasticity in prostate cancer. J Clin Invest. 2025 Jun 02; 135(11). View on PubMed
  17. Yadav S, Tuchayi AM, Moradpour M, Jiang F, Juarez R, de Kouchkovsky I, Flavell RR, Aggarwal RR, Hope TA. Pre- or post-chemotherapy: effect on PSMA uptake. EJNMMI Res. 2025 Apr 07; 15(1):36. View on PubMed
  18. Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, Aggarwal R, Chandrasekar T, Costa D, Drakaki A, Eggener S, Emamekhoo H, Geynisman DM, Graham L, Humphrey P, Leuva H, Levine EG, Luckenbaugh A, Maughan BL, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Reichert Z, Rwigema JC, Saylor P, Shah A, Shah S, Singla N, Sircar K, VanderWeele D, Zhumkhawala A, Montgomery S, Sliker B. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025 04; 23(4). View on PubMed
  19. Feng EM, Vo-Phamhi J, Subramanian AN, Dias M, Foye A, Vinson J, Hong JC, Freedland SJ, Alumkal JJ, Beltran H, Morrissey C, Nelson PS, Chinnaiyan AM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG, Chen WS. Racial variation in the advanced prostate cancer genome. Prostate Cancer Prostatic Dis. 2025 Dec; 28(4):902-907. View on PubMed
  20. Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2025 Aug; 52(10):3700-3708. View on PubMed

Go to UCSF Profiles, powered by CTSI